Atossa Therapeutics Financials - Benzinga

Atossa Therapeutics Inc

ATOSNASDAQ

Trade with Public

Trade with Public

$2.36

-0.06-2.48%

At close: Aug 7, 5:00 PM EST

$2.27

-0.093-3.94%

After Hours: Aug 7, 6:33 PM EST

Earnings: Q2 2026 Earnings were released on Fri Aug 7th, before the market open

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Atossa Therapeutics Financials

Atossa Therapeutics (ATOS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share

Benzinga Newsdesk

PRO
Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.94) by 19.35 percent. This is a 344 percent decrease over losses of $(0.25) per share

Benzinga Newsdesk

PRO
Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 55.22 percent. This is a 88 percent increase over losses of $(0.25) per share from

Benzinga Newsdesk

PRO
Atossa Therapeutics Q3 EPS $(0.07), Inline

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year.

Benzinga Newsdesk

PRO
Atossa Therapeutics Q2 EPS $(0.07) Misses $(0.06) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 20.69 percent. This is a 40 percent decrease over losses of $(0.05) per share

Benzinga Newsdesk

PRO
Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year.

Benzinga Newsdesk